



# Abbott Laboratories (Pakistan) Limited

City Office:  
8th Floor Faysal House  
ST-02, Sharah-e-Faisal,  
Karachi-75350  
P.O. Box 7229 Karachi.  
Tel: +92-21-32799018-19

# Abbott Laboratories (Pakistan) Limited

Registered Office:  
Opp. Radio Pakistan Transmission Centre,  
Hyderabad Road, Landhi, Karachi-75120  
P.O. Box 7229 Karachi 74400  
Tel: +92-21-111-Abbott (111-222-688)

August 27th, 2025

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi

## Sub: Financial Results for the Half Year Ended June 30th 2025

Dear Sir,

We have to inform you that the Board of Directors of our company in their meeting held on Wednesday, August 27th, 2025 at 03:30 p.m. at Abbott Laboratories (Pakistan) Limited, 8th Floor, Faysal House, Shahrah-e-Faisal, Karachi, considered and approved the financial results of the Company as follows:

	<u>Six Months Ended</u>		<u>Three Months Ended</u>	
	June 30, 2025	June 30, 2024	June 30, 2025	June 30, 2024
----- (Rupees in '000) -----				
<b>Sales - net</b>				
Local	34,913,845	30,489,133	18,057,357	15,250,404
Export	1,493,944	1,710,400	1,003,981	920,201
	<u>36,407,789</u>	<u>32,199,533</u>	<u>19,061,338</u>	<u>16,170,605</u>
<b>Cost of sales</b>	(23,792,889)	(23,879,780)	(12,288,344)	(12,301,655)
<b>Gross Profit</b>	<u>12,614,900</u>	<u>8,319,753</u>	<u>6,772,994</u>	<u>3,868,950</u>
<b>Selling and distribution expenses</b>	(5,527,267)	(4,715,510)	(2,805,964)	(2,317,942)
<b>Administrative expenses</b>	(638,196)	(556,903)	(335,172)	(288,168)
<b>Other charges</b>	(826,334)	(308,395)	(504,514)	(131,120)
<b>Other income</b>	416,745	458,108	156,646	202,567
	<u>(6,575,051)</u>	<u>(5,122,700)</u>	<u>(3,489,004)</u>	<u>(2,534,663)</u>
<b>Finance costs</b>	6,039,849	3,197,053	3,283,990	1,334,287
	<u>(37,704)</u>	<u>(12,599)</u>	<u>(33,757)</u>	<u>(5,938)</u>
<b>Profit before minimum tax differential and income tax</b>	<u>6,002,145</u>	<u>3,184,454</u>	<u>3,250,233</u>	<u>1,328,349</u>
<b>Minimum tax differential</b>	-	(166,882)	-	(66,258)
<b>Profit before income tax</b>	<u>6,002,145</u>	<u>3,017,572</u>	<u>3,250,233</u>	<u>1,262,091</u>
<b>Income tax</b>				
Current	(2,647,573)	(731,092)	(1,416,360)	(558,481)
Deferred	188,600	(146,340)	109,626	(82,230)
	<u>(2,458,973)</u>	<u>(877,432)</u>	<u>(1,306,734)</u>	<u>(640,711)</u>
<b>Profit for the period</b>	<u>3,543,172</u>	<u>2,140,140</u>	<u>1,943,499</u>	<u>621,380</u>
<b>Earnings per share - basic and diluted</b>	<u>36.19</u>	<u>21.86</u>	<u>19.85</u>	<u>6.35</u>



The Quarterly Report of the Company for the period ended June 30, 2025 will be transmitted through PUCARS separately, within the specified time.

Yours faithfully,  
ABBOTT LABORATORIES (PAKISTAN) LIMITED

SYED ANIS AHMED  
CHIEF EXECUTIVE &  
MANAGING DIRECTOR

**ABBOTT LABORATORIES (PAKISTAN) LIMITED**  
**CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION**  
**AS AT JUNE 30, 2025**

		June 30, 2025	December 31, 2024
	Note	----- Rupees in '000 ----- (Un-audited)	(Audited)
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	7	15,231,418	14,252,797
Intangible assets		937	1,250
Long-term loans and advances		124,061	114,226
Long-term deposits		32,713	7,513
Long-term prepayments		11,081	13,710
<b>Total non-current assets</b>		<b>15,400,210</b>	<b>14,389,496</b>
<b>CURRENT ASSETS</b>			
Stores and spares		535,784	529,619
Stock-in-trade	8	13,129,576	10,694,515
Trade debts		2,894,055	2,982,679
Loans and advances		1,256,921	938,021
Trade deposits and short-term prepayments		522,591	283,813
Other receivables		1,183,723	1,182,530
Taxation - net		90,717	468,136
Cash and cash equivalents	9	7,174,446	6,182,349
<b>Total current assets</b>		<b>26,787,813</b>	<b>23,261,662</b>
<b>TOTAL ASSETS</b>		<b>42,188,023</b>	<b>37,651,158</b>
<b>EQUITY AND LIABILITIES</b>			
<b>SHARE CAPITAL AND RESERVES</b>			
<b>Authorised capital</b>			
200,000,000 (December 31, 2024: 200,000,000)			
Ordinary shares of Rs.10 /- each		2,000,000	2,000,000
<b>Issued, subscribed and paid-up capital</b>			
97,900,302 (December 31, 2024: 97,900,302)			
Ordinary shares of Rs. 10 /- each	10	979,003	979,003
<b>Reserves</b>			
Capital		1,897,756	1,750,481
Revenue		23,559,321	20,995,152
<b>Total equity</b>		<b>26,436,080</b>	<b>23,724,636</b>
<b>NON-CURRENT LIABILITIES</b>			
Deferred taxation - net		863,987	1,052,587
Staff retirement benefits		1,217,652	1,184,179
Lease liabilities	11	381,654	29,545
<b>Total non-current liabilities</b>		<b>2,463,293</b>	<b>2,266,311</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables	12	12,276,226	10,951,662
Unclaimed dividends		72,460	63,715
Unpaid dividends		209,714	-
Current maturity of lease liabilities	11	78,828	22,683
Provisions		651,422	622,151
<b>Total current liabilities</b>		<b>13,288,650</b>	<b>11,660,211</b>
<b>CONTINGENCIES AND COMMITMENTS</b>			
<b>TOTAL EQUITY AND LIABILITIES</b>	13	<b>42,188,023</b>	<b>37,651,158</b>

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE OFFICER

DIRECTOR

CHIEF FINANCIAL OFFICER

**ABBOTT LABORATORIES (PAKISTAN) LIMITED**  
**CONDENSED INTERIM STATEMENT OF CASH FLOWS**  
**FOR THE SIX MONTHS ENDED JUNE 30, 2025**  
**(UN-AUDITED)**

	Note	June 30, 2025 ---- Rupees in '000 ----	June 30, 2024
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Cash generated from operations	16	5,442,215	1,981,122
Income tax paid		(2,270,154)	(1,297,698)
Minimum tax differential paid		-	(166,882)
Long-term loans and advances - net		(9,835)	(9,371)
Long-term deposits - net		(25,200)	-
Long-term prepayments - net		2,629	(5,754)
Contributions to staff retirement benefit funds		(166,366)	(143,120)
Net movement in provisions		29,271	-
Net cash generated from operating activities		<u>3,002,560</u>	<u>358,297</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Additions to property, plant and equipment		(1,558,597)	(1,040,181)
Sale proceeds from disposal of operating fixed assets		150,585	53,602
Interest income		201,732	239,125
Net cash used in investing activities		<u>(1,206,280)</u>	<u>(747,454)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Bank charges paid		(5,073)	(4,883)
Interest portion of lease liabilities paid		(18,105)	(12,391)
Principal portion of lease liabilities paid		(20,461)	(77,532)
Dividends paid		(760,544)	(1,030,333)
Net cash used in financing activities		<u>(804,183)</u>	<u>(1,125,139)</u>
Net increase / (decrease) in cash and cash equivalents		992,097	(1,514,296)
Cash and cash equivalents at the beginning of the period		6,182,349	5,036,712
Cash and cash equivalents at the end of the period		<u>7,174,446</u>	<u>3,522,416</u>

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

  
**CHIEF EXECUTIVE OFFICER**

  
**DIRECTOR**

  
**CHIEF FINANCIAL OFFICER**



**ABBOTT LABORATORIES (PAKISTAN) LIMITED**  
**CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY**  
**FOR THE SIX MONTHS ENDED JUNE 30, 2025**

	Issued, subscribed and paid-up capital	Reserves					Total equity
		Capital reserves		Revenue reserves		Total	
		Reserve arising on merger	Share based compensation reserve	General reserve	Un- appropriated profit		
Rupees in '000							
Balance as at January 1, 2024 (Audited)	979,003	46,097	1,391,065	5,338,422	10,482,759	17,258,343	18,237,346
Employee benefit cost under IFRS 2 - 'Share based payments'	-	-	163,628	-	-	163,628	163,628
Total comprehensive income for the period ended June 30, 2024							
Profit for the period	-	-	-	-	2,140,140	2,140,140	2,140,140
Other comprehensive income for the period - net of tax	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	2,140,140	2,140,140	2,140,140
Balance as at June 30, 2024 (Un-audited)	979,003	46,097	1,554,693	5,338,422	12,622,899	19,562,111	20,541,114
Balance as at January 01, 2025 (Audited)	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636
Final dividend for the year ended December 31, 2024 @ Rs. 10/- per share	-	-	-	-	(979,003)	(979,003)	(979,003)
Employee benefit cost under IFRS 2 - 'Share based payments'	-	-	147,275	-	-	147,275	147,275
Total comprehensive income for the period ended June 30, 2025							
Profit for the period	-	-	-	-	3,543,172	3,543,172	3,543,172
Other comprehensive income for the period - net of tax	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	3,543,172	3,543,172	3,543,172
Balance as at June 30, 2025 (Un-audited)	979,003	46,097	1,851,659	5,338,422	18,220,899	25,457,077	26,436,080

The annexed notes 1 to 21 form an integral part of these condensed interim financial statements.

CHIEF EXECUTIVE OFFICER

DIRECTOR

CHIEF FINANCIAL OFFICER